1. Home
  2. EWTX vs PRG Comparison

EWTX vs PRG Comparison

Compare EWTX & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • PRG
  • Stock Information
  • Founded
  • EWTX 2017
  • PRG 2020
  • Country
  • EWTX United States
  • PRG United States
  • Employees
  • EWTX N/A
  • PRG N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • PRG Diversified Commercial Services
  • Sector
  • EWTX Health Care
  • PRG Consumer Discretionary
  • Exchange
  • EWTX Nasdaq
  • PRG Nasdaq
  • Market Cap
  • EWTX 1.6B
  • PRG 1.4B
  • IPO Year
  • EWTX 2021
  • PRG N/A
  • Fundamental
  • Price
  • EWTX $15.40
  • PRG $32.64
  • Analyst Decision
  • EWTX Buy
  • PRG Hold
  • Analyst Count
  • EWTX 10
  • PRG 6
  • Target Price
  • EWTX $37.90
  • PRG $35.50
  • AVG Volume (30 Days)
  • EWTX 875.0K
  • PRG 359.4K
  • Earning Date
  • EWTX 11-06-2025
  • PRG 10-22-2025
  • Dividend Yield
  • EWTX N/A
  • PRG 1.60%
  • EPS Growth
  • EWTX N/A
  • PRG 109.72
  • EPS
  • EWTX N/A
  • PRG 5.11
  • Revenue
  • EWTX N/A
  • PRG $2,518,216,000.00
  • Revenue This Year
  • EWTX N/A
  • PRG $1.44
  • Revenue Next Year
  • EWTX N/A
  • PRG $3.56
  • P/E Ratio
  • EWTX N/A
  • PRG $6.36
  • Revenue Growth
  • EWTX N/A
  • PRG 5.17
  • 52 Week Low
  • EWTX $10.60
  • PRG $23.50
  • 52 Week High
  • EWTX $38.12
  • PRG $49.90
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 51.61
  • PRG 53.03
  • Support Level
  • EWTX $14.88
  • PRG $30.99
  • Resistance Level
  • EWTX $16.08
  • PRG $32.10
  • Average True Range (ATR)
  • EWTX 0.85
  • PRG 0.84
  • MACD
  • EWTX -0.04
  • PRG 0.13
  • Stochastic Oscillator
  • EWTX 50.88
  • PRG 98.10

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: